BACKGROUND: The management of pleural neoplasms, specifically mesothelioma, remains difficult. We performed a phase I trial in 54 patients with isolated hemithorax pleural malignancy to determine (a) the feasibility of intraoperative, intrapleural photodynamic therapy after debulking surgery; (b) the influence of light dose/sensitizer interval on postoperative morbidity in order to define the photodynamic therapy (PDT) maximal tolerated dose (MTD); and (c) whether first order dosimetry could be applied to this complex geometry. METHODS: Cohorts of three patients were given escalating intraoperative light doses of 15-35 J/cm2 48 h after i.v. delivery of 2.0 mg/kg Photofrin II (Quadra Logic Technologies, Vancouver, British Columbia, Canada), and then escalating light doses of 30-32.5 J/cm2 after a 24-h sensitizer/operation interval. Twelve patients could not be debulked to the prerequisite 5 mm residual tumor thickness. The remaining 42 patients underwent 19 modified pleuropneumonectomies, five lobectomy-pleurectomies, and 18 pleurectomies. Intrapleural PDT was delivered using 630 nm light from two argon pump-dye lasers, and real-time and cumulative light doses were monitored using seven uniquely designed, computer-interfaced photodiodes. RESULTS: There was one 30-day mortality from intraoperative hemorrhage. In the 48-h sensitizer/operation group (n = 33), possible PDT-related complications included an empyema with late hemorrhage in one of three patients at 17.5 J/cm2 and a bronchopleural fistula at 35 J/cm2. At each of these light doses, three additional patients were treated without complication. Two patients subjected to 24-h sensitizer dosing and 32.5 J/cm2 developed esophageal perforations after pleuropneumonectomy at identical sites. The MTD was declared as 30 J/cm2 light with a 24-h dosing interval when none of the six patients (three original, three repeat) at that level developed toxicity. CONCLUSIONS: These data demonstrate that resection and intrapleural PDT can be performed safely with currently available sensitizers and lasers. Phase II and III trials are now warranted at this MTD in a homogeneous population of patients with pleural malignancies.
BACKGROUND: The management of pleural neoplasms, specifically mesothelioma, remains difficult. We performed a phase I trial in 54 patients with isolated hemithorax pleural malignancy to determine (a) the feasibility of intraoperative, intrapleural photodynamic therapy after debulking surgery; (b) the influence of light dose/sensitizer interval on postoperative morbidity in order to define the photodynamic therapy (PDT) maximal tolerated dose (MTD); and (c) whether first order dosimetry could be applied to this complex geometry. METHODS: Cohorts of three patients were given escalating intraoperative light doses of 15-35 J/cm2 48 h after i.v. delivery of 2.0 mg/kg Photofrin II (Quadra Logic Technologies, Vancouver, British Columbia, Canada), and then escalating light doses of 30-32.5 J/cm2 after a 24-h sensitizer/operation interval. Twelve patients could not be debulked to the prerequisite 5 mm residual tumor thickness. The remaining 42 patients underwent 19 modified pleuropneumonectomies, five lobectomy-pleurectomies, and 18 pleurectomies. Intrapleural PDT was delivered using 630 nm light from two argon pump-dye lasers, and real-time and cumulative light doses were monitored using seven uniquely designed, computer-interfaced photodiodes. RESULTS: There was one 30-day mortality from intraoperative hemorrhage. In the 48-h sensitizer/operation group (n = 33), possible PDT-related complications included an empyema with late hemorrhage in one of three patients at 17.5 J/cm2 and a bronchopleural fistula at 35 J/cm2. At each of these light doses, three additional patients were treated without complication. Two patients subjected to 24-h sensitizer dosing and 32.5 J/cm2 developed esophageal perforations after pleuropneumonectomy at identical sites. The MTD was declared as 30 J/cm2 light with a 24-h dosing interval when none of the six patients (three original, three repeat) at that level developed toxicity. CONCLUSIONS: These data demonstrate that resection and intrapleural PDT can be performed safely with currently available sensitizers and lasers. Phase II and III trials are now warranted at this MTD in a homogeneous population of patients with pleural malignancies.
Authors: T F DeLaney; P D Smith; G F Thomas; Z A Tochner; W F Sindelar; H I Pass; F S Harrington; R F Bonner; J B Mitchell Journal: J Clin Laser Med Surg Date: 1991-10
Authors: W F Sindelar; T F DeLaney; Z Tochner; G F Thomas; L J Dachoswki; P D Smith; W S Friauf; J W Cole; E Glatstein Journal: Arch Surg Date: 1991-03
Authors: Timothy C Zhu; Xing Liang; Julia Sandell; Jarod C Finlay; Andreea Dimofte; Carmen Rodriguez; Keith Cengel; Joseph Friedberg; Stephen M Hahn; Eli Glatstein Journal: Proc SPIE Int Soc Opt Eng Date: 2012-02-13
Authors: Timothy C Zhu; Xing Liang; Chang Chang; Julia Sandell; Jarod C Finlay; Andreea Dimofte; Carmen Rodrigeus; Keith Cengel; Joseph Friedberg; Eli Glatstein; Stephen M Hahn Journal: Proc SPIE Int Soc Opt Eng Date: 2011-02-28
Authors: Timothy C Zhu; Joseph S Friedberg; Andrea Dimofte; Jeremy Miles; James Metz; Eli Glatstein; Stephen M Hahn Journal: Proc SPIE Int Soc Opt Eng Date: 2002-06-06
Authors: Nathalia Ramos da Silva; Daniela Garcia Ribeiro; João Paulo Mardegan Issa; Karla Bonfá; Michelli Sobreiro Menezes; Viviane de Cássia Oliveira; Raphael Freitas de Souza Journal: Lasers Med Sci Date: 2017-05-15 Impact factor: 3.161
Authors: Timothy C Zhu; Michele M Kim; Xing Liang; Baochang Liu; Julia L Meo; Jarod C Finlay; Andreea Dimofte; Carmen Rodriguez; Charles B Simone; Keith Cengel; Joseph S Friedberg Journal: Proc SPIE Int Soc Opt Eng Date: 2013-02-02
Authors: Timothy C Zhu; Michele M Kim; Steve L Jacques; Rozhin Penjweini; Andreea Dimofte; Jarod C Finlay; Charles B Simone; Keith A Cengel; Joseph Friedberg Journal: Proc SPIE Int Soc Opt Eng Date: 2015-03-02
Authors: Craig E Grossman; Stephen Pickup; Amy Durham; E Paul Wileyto; Mary E Putt; Theresa M Busch Journal: Lasers Surg Med Date: 2011-09 Impact factor: 4.025